Arginine-linked HPV-associated E7 Displaying Bacteria-derived Outer Membrane Vesicles As a Potent Antigen-specific Cancer Vaccine

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Apr 22

PMID 38649894

Authors

Suyang Wang

Chao-Cheng Chen

Ming-Hung Hu

Michelle Cheng

Hsin-Fang Tu

Ya-Chea Tsai

Jr-Ming Yang

T C Wu

Chuan-Hsiang Huang

Chien-Fu Hung

Affiliations

Soon will be listed here.

Abstract

Background: Bacteria-based cancer therapy have demonstrated innovative strategies to combat tumors. Recent studies have focused on gram-negative bacterial outer membrane vesicles (OMVs) as a novel cancer immunotherapy strategy due to its intrinsic properties as a versatile carrier.

Method: Here, we developed an Human Papillomavirus (HPV)-associated E7 antigen displaying Salmonella-derived OMV vaccine, utilizing a Poly(L-arginine) cell penetrating peptide (CPP) to enhance HPV16 E7 (aa49-67) H-2 Db and OMV affinity, termed SOMV-9RE7.

Results: Due to OMV's intrinsic immunogenic properties, SOMV-9RE7 effectively activates adaptive immunity through antigen-presenting cell uptake and antigen cross-presentation. Vaccination of engineered OMVs shows immediate tumor suppression and recruitment of infiltrating tumor-reactive immune cells.

Conclusion: The simplicity of the arginine coating strategy boasts the versatility of immuno-stimulating OMVs that can be broadly implemented to personalized bacterial immunotherapeutic applications.

Citing Articles

Innovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy.

Li G, Pu S, You L, Gao Y, Zhong Y, Zhao H Pharmaceutics. 2025; 17(1).

PMID: 39861706 PMC: 11768367. DOI: 10.3390/pharmaceutics17010058.

Bacterial Outer Membrane Vesicle (OMV)-Encapsulated TiO Nanoparticles: A Dual-Action Strategy for Enhanced Radiotherapy and Immunomodulation in Oral Cancer Treatment.

Kan S, Zhang L, Wang Y, Chiang C, Chen M, Huang S Nanomaterials (Basel). 2024; 14(24).

PMID: 39728581 PMC: 11678132. DOI: 10.3390/nano14242045.

Salmonella-based therapeutic strategies: improving tumor microenvironment and bringing new hope for cancer immunotherapy.

He X, Guo J, Bai Y, Sun H, Yang J Med Oncol. 2024; 42(1):27.

PMID: 39666238 DOI: 10.1007/s12032-024-02578-0.

References

Pan J, Li X, Shao B, Xu F, Huang X, Guo X . Self-Blockade of PD-L1 with Bacteria-Derived Outer-Membrane Vesicle for Enhanced Cancer Immunotherapy. Adv Mater. 2021; 34(7):e2106307. DOI: 10.1002/adma.202106307. View

Ma Y, Yang A, Peng S, Qiu J, Farmer E, Hung C . Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model. Vaccine. 2017; 35(31):3850-3858. PMC: 5524135. DOI: 10.1016/j.vaccine.2017.05.081. View

Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L . Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023; 8(1):9. PMC: 9816309. DOI: 10.1038/s41392-022-01270-x. View

Chen Q, Bai H, Wu W, Huang G, Li Y, Wu M . Bioengineering Bacterial Vesicle-Coated Polymeric Nanomedicine for Enhanced Cancer Immunotherapy and Metastasis Prevention. Nano Lett. 2019; 20(1):11-21. DOI: 10.1021/acs.nanolett.9b02182. View

Cecil J, Sirisaengtaksin N, OBrien-Simpson N, Krachler A . Outer Membrane Vesicle-Host Cell Interactions. Microbiol Spectr. 2019; 7(1). PMC: 6352913. DOI: 10.1128/microbiolspec.PSIB-0001-2018. View

Zheng K, Feng Y, Li L, Kong F, Gao J, Kong X . Engineered bacterial outer membrane vesicles: a versatile bacteria-based weapon against gastrointestinal tumors. Theranostics. 2024; 14(2):761-787. PMC: 10758051. DOI: 10.7150/thno.85917. View

Zhou S, Gravekamp C, Bermudes D, Liu K . Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018; 18(12):727-743. PMC: 6902869. DOI: 10.1038/s41568-018-0070-z. View

Huang X, Pan J, Xu F, Shao B, Wang Y, Guo X . Bacteria-Based Cancer Immunotherapy. Adv Sci (Weinh). 2021; 8(7):2003572. PMC: 8025040. DOI: 10.1002/advs.202003572. View

Wang T, Ling M, Shih I, Pham T, Pai S, Lu Z . Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther. 2000; 7(9):726-33. DOI: 10.1038/sj.gt.3301160. View

10.

DeStefano Shields C, White J, Chung L, Wenzel A, Hicks J, Tam A . Bacterial-Driven Inflammation and Mutant Expression Combine to Promote Murine Colon Tumorigenesis That Is Sensitive to Immune Checkpoint Therapy. Cancer Discov. 2021; 11(7):1792-1807. PMC: 8295175. DOI: 10.1158/2159-8290.CD-20-0770. View

11.

Fuchs S, Raines R . Polyarginine as a multifunctional fusion tag. Protein Sci. 2005; 14(6):1538-44. PMC: 2253384. DOI: 10.1110/ps.051393805. View

12.

Wang S, Cheng M, Chen C, Chang C, Tsai Y, Yang J . immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I interferon combination therapy. Oncoimmunology. 2024; 13(1):2298444. PMC: 10761047. DOI: 10.1080/2162402X.2023.2298444. View

13.

Kung Y, Lam B, Tseng S, MacDonald A, Tu H, Wang S . Localization of Salmonella and albumin-IL-2 to the tumor microenvironment augments anticancer T cell immunity. J Biomed Sci. 2022; 29(1):57. PMC: 9373295. DOI: 10.1186/s12929-022-00841-y. View

14.

Batista J, Leal F, Fukuda T, Alcoforado Diniz J, Almeida F, Pupo M . Interplay between two quorum sensing-regulated pathways, violacein biosynthesis and VacJ/Yrb, dictates outer membrane vesicle biogenesis in Chromobacterium violaceum. Environ Microbiol. 2020; 22(6):2432-2442. DOI: 10.1111/1462-2920.15033. View

15.

Bai J, Kim S, Ryu S, Yoon H . Identification and characterization of outer membrane vesicle-associated proteins in Salmonella enterica serovar Typhimurium. Infect Immun. 2014; 82(10):4001-10. PMC: 4187864. DOI: 10.1128/IAI.01416-13. View

16.

Zhuang Q, Xu J, Deng D, Chao T, Li J, Zhang R . Bacteria-derived membrane vesicles to advance targeted photothermal tumor ablation. Biomaterials. 2020; 268:120550. DOI: 10.1016/j.biomaterials.2020.120550. View

17.

Bierwagen J, Wiegand M, Laakmann K, Danov O, Limburg H, Herbel S . Bacterial vesicles block viral replication in macrophages via TLR4-TRIF-axis. Cell Commun Signal. 2023; 21(1):65. PMC: 10045439. DOI: 10.1186/s12964-023-01086-4. View

18.

Kim O, Park H, Dinh N, Choi S, Lee J, Kim J . Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat Commun. 2017; 8(1):626. PMC: 5606984. DOI: 10.1038/s41467-017-00729-8. View

19.

Shimu A, Wei H, Li Q, Zheng X, Li B . The new progress in cancer immunotherapy. Clin Exp Med. 2022; 23(3):553-567. PMC: 10284946. DOI: 10.1007/s10238-022-00887-0. View

20.

Gambhira R, Karanam B, Jagu S, Roberts J, Buck C, Bossis I . A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol. 2007; 81(24):13927-31. PMC: 2168823. DOI: 10.1128/JVI.00936-07. View